标签归档：mrna

pharna mRNA目录

发表于由

PhaRNA，LLC是一家总部位于德克萨斯州休斯顿的生物技术公司，由博士科学家和企业家创立，他们在药物产品的设计和应用方面拥有丰富的专业知识，包括小分子和长（> 150 b）RNA产品。

PhaRNA融合了其创始人的广泛专业知识，为基础和转化研究（包括临床前，临床，美容和兽医应用）创新RNA的设计和生产。

我们先进的研发RNA实验室与我们即将推出的GMP设施相辅相成，这将使我们能够提供高质量的RNA产品，用于IND前期和IND实现的功效和毒性研究。

PhaRNA拥有世界上大的信使RNA模拟（mRNA模拟物）产品档案，用于研究和开发活动。PhaRNA的mRNA模拟物代表天然mRNA类似物或修饰的信使RNA（mmRNA）转录物。PhaRNA，LLC专门设计和合成长（> 150 b）RNA，包括融合和/或Bi- / Poly-cistronic mRNA模拟构建体以及长非编码RNA（lncRNA）产物。

 

pharna mRNA目录

 

 

Embryonic Stem Cells

RNA ENCODED PROTEIN SPECIES CATALOG NUMBER FROM PRICE
BioCapTM POU5F1 mRNA POU domain, class 5, transcription factor 1 Human 1000101 100 ug $300
BioCapTM KLF4 mRNA Krueppel-like factor 4 Human 1000201 100 ug $300
BioCapTM SOX2 mRNA Transcription factor SOX-2 Human 1000301 100 ug $300
BioCapTM MYC mRNA Myc proto-oncogene protein Human 1000401 100 ug $300
BioCapTM LIN28A mRNA Protein lin-28 homolog A Human 1000501 100 ug $300
BioCapTM NANOG mRNA Homeobox protein NANOG Human 1000601 100 ug $300

Endothelial Differentiation Factors

RNA ENCODED PROTEIN SPECIES CATALOG NUMBER FROM PRICE
BioCapTM CDH5 mRNA Cadherin-5 Human 1000701 500 ug $1,550
BioCapTM ETV2 mRNA ETS translocation variant 2 Human 1000801 500 ug $1,550
BioCapTM FLI1 mRNA Friend leukemia integration 1 transcription factor Human 1000901 500 ug $1,550
BioCapTM GATA2 mRNA Endothelial transcription factor GATA-2 Human 1001001 500 ug $1,550
BioCapTM MYB mRNA Transcriptional activator Myb Human 1001101 500 ug $1,550
BioCapTM PECAM1 mRNA Platelet endothelial cell adhesion molecule Human 1001201 500 ug $1,550
BioCapTM RUNX1 mRNA Runt-related transcription factor 1 Human 1001301 500 ug $1,550
BioCapTM VEGFA mRNA Vascular endothelial growth factor A Human 1001401 500 ug $1,550
BioCapTM VEGFB mRNA Vascular endothelial growth factor B Human 1001501 500 ug $1,550

Cardiomyocyte and Myocyte Differentiation Factors

RNA ENCODED PROTEIN SPECIES CATALOG NUMBER FROM PRICE
BioCapTM GATA4 mRNA Transcription factor GATA-4 Human 1001601 500 ug $1,550
BioCapTM MEF2A mRNA Myocyte-specific enhancer factor 2A Human 1001701 500 ug $1,550
BioCapTM MEF2C mRNA Myocyte-specific enhancer factor 2C Human 1001801 500 ug $1,550
BioCapTM MESP1 mRNA Mesoderm posterior protein 1 Human 1001901 500 ug $1,550
BioCapTM MYOD1 mRNA Myoblast determination protein 1 Human 1002001 500 ug $1,550
BioCapTM TBX5 mRNA T-box transcription factor TBX5 Human 1002101 500 ug $1,550

Blood and Hematopoietic Differentiation Factors

RNA ENCODED PROTEIN SPECIES CATALOG NUMBER FROM PRICE
BioCapTM GATA1 mRNA Erythroid transcription factor Human 1002201 500 ug $1,550
BioCapTM GATA3 mRNA Trans-acting T-cell-specific transcription factor GATA-3 Human 1002301 500 ug $1,550
BioCapTM GATA4 mRNA Transcription factor GATA-4 Human 1002401 500 ug $1,550
BioCapTM GATA4 G296S Mutant mRNA Transcription factor GATA-4 G296S Mutant Human 1002501 500 ug $1,550

Beta Cell Differentiation Factors

RNA ENCODED PROTEIN SPECIES CATALOG NUMBER FROM PRICE
BioCapTM MAFA mRNA Transcription factor MafA Human 1002601 500 ug $1,550
BioCapTM NEUROG3 mRNA Neurogenin-3 Human 1002701 500 ug $1,550
BioCapTM PDX1 mRNA Pancreas/duodenum homeobox protein 1 Human 1002801 500 ug $1,550
BioCapTM UL48 mRNA Tegument protein VP16 HHV-1 1002901 500 ug $1,550

Hepatocyte Differentiation Factors

RNA ENCODED PROTEIN SPECIES CATALOG NUMBER FROM PRICE
BioCapTM FOXA1 mRNA Hepatocyte nuclear factor 3-alpha Human 1003001 500 ug $1,550
BioCapTM FOXA2 mRNA Hepatocyte nuclear factor 3-beta Human 1003101 500 ug $1,550
BioCapTM FOXA3 mRNA Hepatocyte nuclear factor 3-gamma Human 1003201 500 ug $1,550
BioCapTM HNF1A mRNA Hepatocyte nuclear factor 1-alpha Human 1003301 500 ug $1,550
BioCapTM HNF1B mRNA Hepatocyte nuclear factor 1-beta Human 1003401 500 ug $1,550

Neuronal Differentiation Factors

RNA ENCODED PROTEIN SPECIES CATALOG NUMBER FROM PRICE
BioCapTM ASCL1 mRNA Achaete-scute homolog 1 Human 1003501 500 ug $1,550
BioCapTM FOXA2 mRNA Hepatocyte nuclear factor 3-beta Human 1003601 500 ug $1,550
BioCapTM ISL1 mRNA Insulin gene enhancer protein ISL-1 Human 1003701 500 ug $1,550
BioCapTM LHX3 mRNA LIM/homeobox protein Lhx3 Human 1003801 500 ug $1,550
BioCapTM LMX1A mRNA LIM homeobox transcription factor 1-alpha Human 1003901 500 ug $1,550
BioCapTM MNX1 mRNA Motor neuron and pancreas homeobox protein 1 Human 1004001 500 ug $1,550
BioCapTM NEUROD1 mRNA Neurogenic differentiation factor 1 Human 1004101 500 ug $1,550
BioCapTM NEUROD2 mRNA Neurogenic differentiation factor 2 Human 1004201 500 ug $1,550
BioCapTM NEUROG2 mRNA Neurogenin-2 Human 1004301 500 ug $1,550
BioCapTM POU3F2 mRNA POU domain, class 3, transcription factor 2 Human 1004401 500 ug $1,550
BioCapTM ZIC1 mRNA Zinc finger protein ZIC 1 Human 1004501 500 ug $1,550
 

牛痘病毒mRNA加帽酶|UCF.ME® mRNA Vaccinia Capping Enzyme GMP-grade

发表于由

牛痘病毒mRNA加帽酶|UCF.ME® mRNA Vaccinia Capping Enzyme GMP-grade

产品说明书

FAQ

COA

已发表文献

Eukaryotes mRNA forms a special structure at the 5'end after transcription, which is the cap structure. The cap structure plays an important role in the stability, transportation and translation of mRNA. Vaccinia virus capping enzyme is an effective enzyme that can catalyze the formation of the cap structure. It’s composed of two subunits D1 and D12. It also has RNA triphosphatase activity, guanylate acyltransferase activity and guanine methyltransferase activity, could connect the 7-methylguanine cap structure (m7Gppp) to the 5'end of the RNA (m7Gppp5'N). Vaccinia virus capping enzyme can cap the RNA at correct direction within one hour when present at suitable concentration of capping buffer, guanosine triphosphate (GTP), S-adenosylmethionine (SAM), etc..

This product is produced in accordance with GMP process requirements and provided in a liquid form, used for in vivo/in vitro pre-translation mRNA capping reaction or mRNA 5'end labeling reaction.

 

Product Properties

Source

Recombinant E. coli with vaccinia virus capping enzyme gene

Optimum Temperature

37℃

Storage Buffer

20 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM DTT, 0.1 mM EDTA, 0.1% Triton X-100, 50% glycerin

Unit Definition

1 unit: The amount of enzyme required to incorporate 10 pmol GTP (α-32P) into a transcript with 80 nucleotides (80 nt) at 37℃ within 1 h. 

 

Contents

Contents No.

Name

Catalog No./Specification

10614ES84

（2 KU）

10614ES92

（10 KU）

10614ES96

（100 KU）

10614ES99

(5 MU)

10614

mRNA Vaccinia Capping Enzyme GMP-grade (10 U/μL)

200 μL

1 mL

10 mL

500 mL

 

Shipping and Storage

mRNA Vaccinia Capping Enzyme GMP-grade products are shipped with dry ice and can be stored at -15℃ ~ -25℃ for one year.

 

Experimental methods

Cap1 capping reaction (20 μL reaction system)

This step is suitable for capping reaction of 10 μg RNA (≥ 100 nt), and can be amplified according to experimental needs.

1. Take 10 μg RNA to a 1.5 mL centrifuge tube and dilute to 12.9 μL with nuclease-free water;

2. Heat at 65°C for 5 min;

3. Take out the centrifuge tube and place it on ice for 5 min;

4. Add the following components in sequence:

Components

Volume

Denatured RNA

12.9 μL

10×Capping Buffer

2.0 μL

Murine RNase inhibitor(40 U/μL)

0.5 μL

GTP (10 mM)

1.0 μL

SAM (10 mM, fresh)

1.6 μL

Vaccinia Capping Enzyme (10 U/μL)

1.0 μL

Cap 2´-O-Methyltransferase (50 U/μL)

1.0 μL

【Note】10×Capping Buffer(Cat# 10666)：0.5 M Tris-HCl, 50 mM KCl, 10 mM MgCl2, 10 mM DTT pH 8.0 @ 25°C.

5. Incubate at 37°C for 2 h;

6. RNA capping is completed, next experiments can be performed.

 

Notes

1. For your safety and health, please wear personal protective equipment (PPE), such as laboratory coats and disposable gloves, when operating with this product.

2. The extracted RNA needs to be purified and resuspended in nuclease-free water;

3. The RNA solution needs to be heated before adding the enzyme to remove the secondary structure at the 5'end;

4. For RNA with a known 5'end structure, the reaction time can be extended to 4 h to improve the capping efficiency;

5. In the 5'end labeling reaction system, the GTP stock solution should be diluted to 1-3 times of the mRNA molar concentration in the reaction system.

HB230818

牛痘病毒mRNA加帽酶|UCF.ME® mRNA Vaccinia Capping Enzyme GMP-grade

暂无内容

牛痘病毒mRNA加帽酶|UCF.ME® mRNA Vaccinia Capping Enzyme GMP-grade

暂无内容

Eukaryotes mRNA forms a special structure at the 5'end after transcription, which is the cap structure. The cap structure plays an important role in the stability, transportation and translation of mRNA. Vaccinia virus capping enzyme is an effective enzyme that can catalyze the formation of the cap structure. It’s composed of two subunits D1 and D12. It also has RNA triphosphatase activity, guanylate acyltransferase activity and guanine methyltransferase activity, could connect the 7-methylguanine cap structure (m7Gppp) to the 5'end of the RNA (m7Gppp5'N). Vaccinia virus capping enzyme can cap the RNA at correct direction within one hour when present at suitable concentration of capping buffer, guanosine triphosphate (GTP), S-adenosylmethionine (SAM), etc..

This product is produced in accordance with GMP process requirements and provided in a liquid form, used for in vivo/in vitro pre-translation mRNA capping reaction or mRNA 5'end labeling reaction.

 

Product Properties

Source

Recombinant E. coli with vaccinia virus capping enzyme gene

Optimum Temperature

37℃

Storage Buffer

20 mM Tris-HCl pH 8.0, 100 mM NaCl, 1 mM DTT, 0.1 mM EDTA, 0.1% Triton X-100, 50% glycerin

Unit Definition

1 unit: The amount of enzyme required to incorporate 10 pmol GTP (α-32P) into a transcript with 80 nucleotides (80 nt) at 37℃ within 1 h. 

 

Contents

Contents No.

Name

Catalog No./Specification

10614ES84

（2 KU）

10614ES92

（10 KU）

10614ES96

（100 KU）

10614ES99

(5 MU)

10614

mRNA Vaccinia Capping Enzyme GMP-grade (10 U/μL)

200 μL

1 mL

10 mL

500 mL

 

Shipping and Storage

mRNA Vaccinia Capping Enzyme GMP-grade products are shipped with dry ice and can be stored at -15℃ ~ -25℃ for one year.

 

Experimental methods

Cap1 capping reaction (20 μL reaction system)

This step is suitable for capping reaction of 10 μg RNA (≥ 100 nt), and can be amplified according to experimental needs.

1. Take 10 μg RNA to a 1.5 mL centrifuge tube and dilute to 12.9 μL with nuclease-free water;

2. Heat at 65°C for 5 min;

3. Take out the centrifuge tube and place it on ice for 5 min;

4. Add the following components in sequence:

Components

Volume

Denatured RNA

12.9 μL

10×Capping Buffer

2.0 μL

Murine RNase inhibitor(40 U/μL)

0.5 μL

GTP (10 mM)

1.0 μL

SAM (10 mM, fresh)

1.6 μL

Vaccinia Capping Enzyme (10 U/μL)

1.0 μL

Cap 2´-O-Methyltransferase (50 U/μL)

1.0 μL

【Note】10×Capping Buffer(Cat# 10666)：0.5 M Tris-HCl, 50 mM KCl, 10 mM MgCl2, 10 mM DTT pH 8.0 @ 25°C.

5. Incubate at 37°C for 2 h;

6. RNA capping is completed, next experiments can be performed.

 

Notes

1. For your safety and health, please wear personal protective equipment (PPE), such as laboratory coats and disposable gloves, when operating with this product.

2. The extracted RNA needs to be purified and resuspended in nuclease-free water;

3. The RNA solution needs to be heated before adding the enzyme to remove the secondary structure at the 5'end;

4. For RNA with a known 5'end structure, the reaction time can be extended to 4 h to improve the capping efficiency;

5. In the 5'end labeling reaction system, the GTP stock solution should be diluted to 1-3 times of the mRNA molar concentration in the reaction system.

HB230818

牛痘病毒mRNA加帽酶|UCF.ME® mRNA Vaccinia Capping Enzyme GMP-grade

暂无内容

牛痘病毒mRNA加帽酶|UCF.ME® mRNA Vaccinia Capping Enzyme GMP-grade

暂无内容

CleanCap™ Cas9 mRNA

发表于由

trilink 

CleanCap™  Cas9 mRNA

CleanCapTM CRISPR 相关蛋白 9 mRNA

目录号trilink L-7606

CleanCap Cas9 mRNA

Cas9 mRNA 表达一个版本的酿脓链球菌 SF370 Cas9 蛋白 (CRISPR Associated protein 9)。Cas9 作为 CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) 基因组编辑系统的一部分发挥作用。在 CRISPR 系统中，一个 RNA 引导序列靶向目标位点，Cas9 蛋白被用来进行双链 DNA 切割。

Cas9 mRNA 编码具有 N 和 C 末端核定位信号 (NLS) 的 Cas9 蛋白。mRNA 内两个 NLS 信号的掺入

增加了传递到细胞核的频率，从而增加了 DNA 剪切的速度。此外，C 末端 HA 表位标签有助于 Cas9 蛋白的检测、分离和纯化。

L-7606-20 (20µg)

L-7606-100 (100µg)

L-7606-1000 (1 mg)

L-7606-BK（原液量）

1.0 mg/mL，溶于 1 mM 柠檬酸钠 (pH 6.4) mRNA 长度：4521 个核苷酸

储存于-40 °C 或以下

QC 分析

鉴别和纯度琼脂糖凝胶迁移率；通过浓度：±6%；通过

产品详情

使用 CleanCap™，TriLink 专有的共转录加盖方法对该 mRNA 加盖，从而得到天然存在的 Cap 1 结构，具有较高的加盖效率。多聚腺苷酸化，并针对哺乳动物系统进行了优化。它模拟了一个*加工的成熟 mRNA。

 

处理

 

在-40 °C 或更低温度下储存。在冰上解冻并处理 mRNA。*使用后，打开前脉冲旋转，并等分至一次性使用部分。请勿涡旋。仅使用经过认证的无 RNase 试剂和具有适当无 RNase 技术的耗材。建议使用屏障。避免冻融循环。不得与含血清的培养基混合，除非首先与稳定转染试剂络合。

 

在 Broad、MIT、Harvard、Iowa、UTokyo 和 Rockefeller（分别称为“研究机构”，统称为“机构”）和 TriLink BioTechnologies LLC (“TriLink”) 向产品买方（“有限被许可方”）授予的有限许可下，提供 Cas9/CRISPR 产品和/或其中包含的技术（“产品”），向有限被许可方传达不可转让的权利，即在有限被许可方按照以下要求开展的内部研究中使用所购买的产品金额：

 

i. 有限被许可方不得向任何其他人士或实体出售或以其他方式转让产品（包括但不限于包含全部或部分产品的任何材料），或为任何其他人士或实体的利益使用产品履行服务，

 

ii. 有限被许可方应仅使用从公司采购的协议产品的采购金额，并应仅将协议产品和协议产品的组分用于其内部研究，但以下情形除外：(a) 任何人类或临床用途，包括但不限于对人类的任何管理或任何诊断或预后用途；(b) 任何人类生殖系修饰，包括对以下各项进行修改：  人类胚胎或人类生殖细胞的 DNA；(c) 任何体内兽医或牲畜使用；(d) 为人类或动物开发、生产、分销、进口、出口、运输、销售、提供销售、营销、推广或其他专有权利或产品的开发或使用，或作为人类或动物的检测服务、治疗或诊断；(e) 根据 1938 年《联邦食品、药品和化妆品法案》第 505 节（经修订）、1944 年《公共健康服务法案》第 351 节（经修订）或任何后续法律或美国以外辖区的同等法律或法规，提供营养益处并由监管机构监管为药物或生物制品的产品；(f) 任何农业用途，包括但不限于使用或

在烟草产品的种植、生长、生产、出口或生产中的应用；及 (g) 任何与基因驱动有关的使用或应用（下称“领域”），但有限被许可方获得机构单独许可在领域外使用产品，而非用于任何商业目的的情况除外，

 

iii. 有限被许可方应按照所有适用法律法规（包括但不限于适用的人类健康和动物福利法律法规）使用产品，

 

  • 机构不得就知识产权或产品向有限被许可方提供任何类型的保证（法定或暗示），包括但不限于产品质量、条件、描述、适销性、特定用途的适合性、不侵犯知识产权或不存在潜在或其他缺陷，并且在此明确否认所有此类保证。

 

v. 研究机构应明确放弃对通过使用产品获得的结果的任何保证，包括但不限于对不准确、无效或不完整结果的任何索赔，

vi. 机构及其董事、受托人、管理人员、雇员、代理人、教员、关联研究者和学生不承担责任

向有限被许可方，包括但不限于任何使用或利润损失、业务中断或任何间接损害赔偿、附带损害赔偿、特殊损害赔偿或其他类型的间接损害赔偿，无论该等损害赔偿是如何造成的，也无论该等损害赔偿是由合同、侵权行为、严格产品责任还是其他行为引起的，

 

vii. 有限被许可方应赔偿、保护 TriLink、各研究机构及其现任和前任受托人、董事、管理人员、教员、附属研究者、学生、雇员和代理人以及其各自的继任者、继承人和受让人，使其免受因行使根据有限许可向有限被许可方授予的任何权利或违反有限许可而产生或施加的任何索赔、诉讼、调查、诉讼、要求或判决所产生的任何责任、损害、损失或费用（包括但不限于合理的律师费和费用）的损害。

该等有限被许可方的许可，但前提是，在法律不允许的范围内，该等有限被许可方同意，在法律允许的范围内，其（而非受偿方）应负责因行使根据有限许可向有限被许可方授予的任何权利或因有限被许可方违反有限许可而产生的或与之相关的任何责任、损害、损失或支出，以及

 

viii. 产品及其使用可能涉及一项或多项已专有技术或一项或多项未决专有技术申请，或  更多机构和产品的购买并未根据前述专有技术申请中针对产品或其使用、生产或商业化提出的任何要求传达许可，除非有限许可中明确规定。

 

TriLink Antigen mRNA 系列 现货供应

发表于由

上海金畔生物科技正规代理Trilink产品，zui近市场出现Trilink的假货，为了您的实验安全请选择正牌代理。 :

 

 

TriLink BioTechnologies——高品质常规/特殊核苷酸产品
TriLink BioTechnologies公司是世界的核酸修饰技术领域的，成立于1996年，总部设在San Diego，California。TriLink公司致力于高品质核酸修饰产品的研发和生产，提供包括核苷酸、常规及核苷三磷酸特殊修饰的寡核苷酸定制（oligonucleotides），m RNA合成，CleanAmp?PCR产品，phosphoramidites和其他小分子在内的众多产品。近二十年来，TriLink一直是诊断和OEM市场核酸产品供应的行业，产品应用于基因治疗，核苷类化疗，寡核苷酸治疗和诊断领域。此外，TriLink还可提供特殊核苷酸、m RNA定制，合同研究服务和ISO/ QSR标准的cGMP生产设施。TriLink完善的产品及研发服务解决方案有助于推动药物发现和生物医学研究。

经过18年的发展， TriLink已经成为高品质RNA合成领域的，为广大科研工作者提供的mRNA及长链RNA（长可达几个Kb），并且定制修饰。同时我们也提供成品mRNA产品，包括报告基因及 mRNA表达因子。

Antigen mRNA for Vaccines and Immunotherapy

mRNA offers several advantages over traditional plasmid and viral-based approaches:

  • mRNA boasts a superior safety profile. As a transient carrier of genetic information, it is metabolized naturally and poses little to no risk of genomic integration. Additionally, no inactivated viruses or pathogens are needed.
  • mRNA serves the dual purpose of expressing the desired antigen as well as acting as an adjuvant.
  • mRNA triggers a more diverse immune response. Because the mRNA encoded epitopes are intracellular, they are recognized by the immune system in an MHC class-independent manner.
  • mRNA can more readily transfect difficult-to-transfect cell types because it functions in the cytoplasm. DNA vaccines can be limited by lack of access to the nucleus.
  • mRNA manufacturing is easily scalable. Because mRNA transcription is carried out compley in vitro, to hundreds of millions of vaccine doses with a lead time of as little as a few weeks. This allows for rapid deployment of a new antigen during pandemics.
  • mRNA is easily customizable. The ease of manufacturing makes it a viable option for personalized treatments.

产品如下:

货号 品名 规格 价格 品牌
Antigen mRNA
L-7610 CleanCap™ OVA mRNA 20 μg  1700 TriLink BioTechnologies
L-7610 CleanCap™ OVA mRNA 100 μg  4080 TriLink BioTechnologies
L-7610 CleanCap™ OVA mRNA 1 mg 21420 TriLink BioTechnologies
L-7610 CleanCap™ OVA mRNA 5 mg (5 x 1 mg)  75990 TriLink BioTechnologies
L-7210 CleanCap™ OVA mRNA (5moU) 20 µgrams  2125 TriLink BioTechnologies
L-7210 CleanCap™ OVA mRNA (5moU) 100 µgrams 5015 TriLink BioTechnologies
L-7210 CleanCap™ OVA mRNA (5moU) 1 mg 26775 TriLink BioTechnologies
L-7210 CleanCap™ OVA mRNA (5moU) 5 mg (5 x 1 mg)  96050 TriLink BioTechnologies

L-7210
CleanCap™ OVA mRNA (5moU)
CleanCap™ Ovalbumin mRNA (5-methoxyuridine) 

 

mRNA Length: 1,437 nucleotides

Concentration: 1.0 mg/mL

Buffer: 1 mM Sodium Citrate, pH 6.4

 

Identity & Purity:

Agarose Gel Mobility; Pass

Concentration ± 5%; Pass

 

Product Insert
SDS

 

Ovalbumin (OVA) is a member of the serpin superfamily and the predominant glycoprotein found in egg whites. It is a commonly used antigen for immunization and biochemical studies and is an established model allergen for airway hyper-responsiveness.

 

This mRNA is capped using CleanCap™, TriLink's proprietary co-transciptional capping method, which results in the naturally occuring Cap 1 structure with high capping efficiency. It is polyadenylated, modified with 5-methoxyuridine and optimized for mammalian systems. It mimics a fully processed mature mRNA.

 

TriLink offers both unmodified and 5-methoxyuridine modified OVA mRNA. Exogenous unmodified mRNA activates the innate immune system and production of cytokines, which will influence the overall induced immune response. mRNA modified with 5-methoxyuridine reduces this effect.
 

Certificate(s) of Analysis

TD-OB06A

 

L-7210 is a replacement for L-6128,

 

Not for resale without express written permission. Not for use in humans. No license under any patent or patent pending is granted or implied by the purchase of any TriLink product. TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser’s sole responsibility.

 

L-7610
CleanCap™ OVA mRNA
CleanCap™ Ovalbumin mRNA 

 

mRNA Length: 1,437 nucleotides

Concentration: 1.0 mg/mL

Buffer: 1 mM Sodium Citrate, pH 6.4

 

Identity & Purity:

Agarose Gel Mobility; Pass

Concentration ± 5%; Pass

 

Product Insert
SDS

 

Ovalbumin (OVA) is a member of the serpin superfamily and the predominant glycoprotein found in egg whites. It is a commonly used antigen for immunization and biochemical studies and is an established model allergen for airway hyper-responsiveness.

 

This mRNA is capped using CleanCap™, TriLink’s proprietary co-transcriptional capping method,

which results in the naturally occurring Cap 1 structure with high capping efficiency. It is polyadenylated and optimized for mammalian systems. It mimics a fully processed mature mRNA.

 

TriLink offers both unmodified and 5-methoxyuridine modified OVA mRNA. Exogenous unmodified mRNA activates the innate immune system and production of cytokines, which will influence the overall induced immune response. mRNA modified with 5-methoxyuridine reduces this effect.

 

Certificate(s) of Analysis

TD-OB07A

 

L-7610 is a replacement for L-6328.

 

Not for resale without express written permission. Not for use in humans. No license under any patent or patent pending is granted or implied by the purchase of any TriLink product. TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser’s sole responsibility.

 

 

 

ozbiosciences mRNA产品简介

发表于由

ozbiosciences mRNA产品简介


mRNA HIGH QUALITY PRODUCTS & CUSTOM SERVICE 

优点#1：它不需要核摄取来表达，因为mRNA的翻译发生在细胞质中。事实上，核递送（通过核膜）是转染慢细胞或非分裂细胞的主要途径之一，因此，mRNA转染对这一目的特别有吸引力。

优点2：这种方法不是综合性的。与pDNA相反，mRNA不能导致遗传

优点#3：非常适合难以转染的细胞。mRNA比DNA有几个优点，可以更容易地对原代和难以转染的细胞进行基因修饰。除了mRNA没有整合到宿主基因组中的风险之外，mRNA转染是细胞周期独立的，特别适合于缓慢分裂的细胞，如内皮细胞或树突状细胞1。

mRNA的益处

-无需核摄取-蛋白质直接在细胞质中表达

–

比DNA转染更快的蛋白质表达

-无基因组整合

-非常适合转染慢细胞或非分裂细胞

-以启动子独立的方式表达蛋白质

-瞬时转染：基于mRNA的蛋白质表达持续时间

5’ Cap

这种帽结构保护mRNA免受降解，并招募加工和翻译因子。在mam-

mals，主要形式是7-甲基鸟苷（Cap 0），通过5'至5'三磷酸桥连接到

在核糖O-2位甲基化的第一转录核苷酸（Cap 1）。

5'非翻译区（5'UTR）

5'UTR是一个非编码区，直接位于转录后启动密码子的上游-

通过调节mRNA稳定性、转运、亚细胞定位和翻译效率因此允许精细控制蛋白质产物。该区域GC含量高几个次级结构，包括Kozak序列（GCCGCCRCUAUGG）在翻译过程的启动中发挥作用。

开放阅读框架（ORF）

真核细胞mRNA的这个内部区域被翻译成蛋白质。ORF以蛋氨酸密码子开始（AUG）并以终止密码子结束。

3'非翻译区（3'UTR）

3'UTR是mRNA中紧接着翻译终止密码子的部分。此区域播放通过影响基因表达的定位、稳定性、输出和翻译效率mRNA。

Poly(A) tail

聚（A）尾是腺嘌呤核苷酸的长序列（0-250个核苷酸，中间长度为50-100

在HeLa和NIH-3T3细胞中）2添加到前mRNA的3’端。

聚（A）尾部含有聚（A）结合蛋白（PABPs）的结合位点，PABPs在出口中起主要作用

从细胞核、翻译和保护降解。它的长度是反式的重要决定因素-

关系效率和mRNA稳定性。这是一个重要因素，因为它的缺失或移除通常会导致

核酸外切酶介导的mRNA降解。

OZ Biosciences mRNAs for mRNA Vaccine:

OVA mRNA 

– ref# MRNA41 (moU)

– ref# MRNA42 (Unmodified)

Designed to produce high expression level of Ovalbumin Protein. That 

is a commonly used antigen for immunization and biochemical studies.

Spike SARS-CoV-2 mRNA

– ref #MRNA35 (moU)

– ref #MRNA34 (Unmodified)

Designed to produce high expression level of Spike Protein of SARS-

COV-2 virus. That is a commonly used antigen for immunization and 

biochemical studies.

Spike DELTA mRNA

– ref #MRNA37 (moU)

– ref #MRNA36 (Unmodified)

Designed to produce high expression level of DELTA Mutant Spike 

Protein of SARS-CoV-2 virus.

Spike OMICRON mRNA

– ref #MRNA39 (moU)

Designed to produce high expression level of OMICRON Mutant Spike 

Protein of SARS-CoV-2 virus.

牛痘病毒加帽酶 mRNA加帽反应|Vaccinia Capping Enzyme

发表于由

牛痘病毒加帽酶 mRNA加帽反应|Vaccinia Capping Enzyme

产品说明书

FAQ

COA

已发表文献

产品描述

真核生物中mRNA经转录后修饰在5'端形成一个特殊结构，即帽子结构，该结构对mRNA的稳定、转运与翻译过程均有较重要作用。牛痘病毒加帽酶是催化形成帽子结构的有效酶，其由D1和D12两个亚基组成，兼具RNA三磷酸酯酶活性、鸟苷酰基转移酶活性和鸟嘌呤甲基转移酶活性，可将7-甲基鸟嘌呤帽结构（m7Gppp）连接到RNA的5'末端（m7Gppp5'N）。牛痘病毒加帽酶，在合适浓度的加帽缓冲液（Capping buffer），鸟苷三磷酸（GTP），S-腺苷甲硫氨酸（SAM）等存在条件下，能够在一个小时之内对RNA进行加帽，并且保证正确的方向。

本品以无菌液体形式提供，可应用于体内/体外翻译前mRNA的加帽反应或mRNA的5'末端标记反应。

 

产品性质

来源（Source）

携带牛痘病毒加帽酶基因的E. coli

最适温度（Optimum Temperature）

37℃

储存缓冲液（Storage Buffer）

20mM Tris-HCl pH 8.0，100 mM NaCl，1 mM DTT，0.1 mM EDTA，0.1% Triton X-100，50%甘油

活性单位定义（Unit Definition）

37℃条件下，1小时内将10 pmol GTP（α- 32P）掺入到一条含80个核苷酸（80nt）转录产物上所需要的酶量，即为1个单位。

 

产品组分

组分编号

组分名称

产品编号/规格

10615ES76

（500 U）

10615ES84

（2000 U）

10615ES92

（10000 U）

10615-A

10×Capping Buffer

150 μL

500 μL

1.25 mL×2

10615-B

Vaccinia Capping Enzyme（10 U/μL）

50 μL

200 μL

1 mL

 

运输和保存方法

干冰运输。 -15℃ ~ -25℃保存，有效期一年。推荐分装保存，避免反复冻融。

 

使用方法

加帽反应（反应体系20 μL）

本步骤适用于10μg RNA（≥ 100 nt）的加帽反应，且可根据实验需要放大。

1. 取10μg RNA至1.5 mL离心管，使用无核酸酶的水稀释至9.5 μL；

2. 65℃加热5 min；

3. 取出离心管置于冰上5 min；

4. 依次加入以下组分：

组分

体积

Denatured RNA

9.5 μL

10×Capping Buffer

2.0 μL

Murine RNase inhibitor(40 U/μL)

0.5 μL

GTP (10 mM)

1.0 μL

SAM (10 mM, fresh)

1.0 μL

Vaccinia Capping Enzyme (10 U/μL)

5.0 μL

Cap 2´-O-Methyltransferase (50 U/μL)

1.0 μL

【注】：10×Capping Buffer(Cat# 10666)：0.5 M Tris-HCl, 50 mM KCl, 10 mM MgCl2, 10 mM DTT pH 8.0 @ 25°C。

5. 37°C孵育2 h；

6. RNA加帽完成，可进行后续实验。

 

注意事项

1. 为了您的安全和健康，请穿实验服并戴一次性手套操作；

2. 所提取的RNA需经过纯化并使用无核酸酶的水重悬；

3. 在加入酶之前需要对RNA溶液进行加热以去除5'末端的二级结构；

4. 对于已知5'末端结构的RNA，可以延长反应时间至4 h，提高加帽效率；

5. 5'末端标记反应体系中，GTP储液应稀释为反应体系中mRNA摩尔浓度的1-3倍。

HB220701

 

Q: 酶法加帽中先升温再降温的目的是什么？在放大生产时好像很难做到先升温再降温。

A: 先升温是为了把RNA二级结构打开，让RNA处于单链状态。如果不进行这步操作的话，会影响加帽的效率。这部分目前的确是工艺生产上的难点。现在有的公司直接在模板序列确定时会对RNA的二级结构作预测，加帽酶只识别mRNA前几个核苷酸，如果确定这部分结构不会产生RNA的二级结构的话，可以不进行加热。

Q: 帽类似物加帽和酶法加帽如何选择？

A: 工业上酶法加帽最常使用的是牛痘病毒加帽酶处理IVT产物可以将其修饰成Cap 0 mRNA，Cap 0结构可以在二氧甲基转移酶（2'O-methyltransferase）的作用下进一步修饰成Cap 1（m7GpppmN）。利用酶法加帽，加帽效率可以达到95%以上。共转录加帽法操作简便，但由于GTP会竞争帽状二聚体，因此该方法加帽率低一些；两种方式各有优缺点。

Q: 加帽优化的方式有哪些？

A: 通过增加VCE的量例如100ul体系加入10ul即100U的酶活，主要是增强VCE的甲基转移酶活性，也可以通过增加SAM（0.5mmol）增强鸟苷转移活性，增加加帽率。例如我们的新款单链加帽酶，它的加帽率显著提升，就是鸟苷转移活性比传统的更好，对于传统VCE，小亚基D12容易沉淀形成聚合物，纯化时容易损失，所以成本更贵，批次不能控制。

Q: 对于一些没有加上帽子的mRNA，会对后续实验比如说做生物制剂等有什么影响？

A: 目前行业对这一块的没有做针对性的去除，行业里面主要是看加帽效率的多少，目前做的比较好的加帽率在80%以上，当然肯定是越高越好了。这个还没有一个绝对的标准。

对于合成之后的mRNA，可以用纯化的方式处理，比如康*的一步膜包，极大的减少了纯化工艺，传统用Oligo d（T）的柱子做纯化，效果好可以回收率70-80%；效果差40-50%，也可以多加一步疏水柱在oligo dT后。

Q: 共转录加帽和两步法加帽对于模板的起始位点的要求？

A: 共转录要求对于模板的起始位点要求必须是 AGG* 开头

两步法对于位点无要求，但我司目前产品对于AGGG起始位点的产量最高，主要是T7酶的偏好性导致。

牛痘病毒加帽酶 mRNA加帽反应|Vaccinia Capping Enzyme

暂无内容

产品描述

真核生物中mRNA经转录后修饰在5'端形成一个特殊结构，即帽子结构，该结构对mRNA的稳定、转运与翻译过程均有较重要作用。牛痘病毒加帽酶是催化形成帽子结构的有效酶，其由D1和D12两个亚基组成，兼具RNA三磷酸酯酶活性、鸟苷酰基转移酶活性和鸟嘌呤甲基转移酶活性，可将7-甲基鸟嘌呤帽结构（m7Gppp）连接到RNA的5'末端（m7Gppp5'N）。牛痘病毒加帽酶，在合适浓度的加帽缓冲液（Capping buffer），鸟苷三磷酸（GTP），S-腺苷甲硫氨酸（SAM）等存在条件下，能够在一个小时之内对RNA进行加帽，并且保证正确的方向。

本品以无菌液体形式提供，可应用于体内/体外翻译前mRNA的加帽反应或mRNA的5'末端标记反应。

 

产品性质

来源（Source）

携带牛痘病毒加帽酶基因的E. coli

最适温度（Optimum Temperature）

37℃

储存缓冲液（Storage Buffer）

20mM Tris-HCl pH 8.0，100 mM NaCl，1 mM DTT，0.1 mM EDTA，0.1% Triton X-100，50%甘油

活性单位定义（Unit Definition）

37℃条件下，1小时内将10 pmol GTP（α- 32P）掺入到一条含80个核苷酸（80nt）转录产物上所需要的酶量，即为1个单位。

 

产品组分

组分编号

组分名称

产品编号/规格

10615ES76

（500 U）

10615ES84

（2000 U）

10615ES92

（10000 U）

10615-A

10×Capping Buffer

150 μL

500 μL

1.25 mL×2

10615-B

Vaccinia Capping Enzyme（10 U/μL）

50 μL

200 μL

1 mL

 

运输和保存方法

干冰运输。 -15℃ ~ -25℃保存，有效期一年。推荐分装保存，避免反复冻融。

 

使用方法

加帽反应（反应体系20 μL）

本步骤适用于10μg RNA（≥ 100 nt）的加帽反应，且可根据实验需要放大。

1. 取10μg RNA至1.5 mL离心管，使用无核酸酶的水稀释至9.5 μL；

2. 65℃加热5 min；

3. 取出离心管置于冰上5 min；

4. 依次加入以下组分：

组分

体积

Denatured RNA

9.5 μL

10×Capping Buffer

2.0 μL

Murine RNase inhibitor(40 U/μL)

0.5 μL

GTP (10 mM)

1.0 μL

SAM (10 mM, fresh)

1.0 μL

Vaccinia Capping Enzyme (10 U/μL)

5.0 μL

Cap 2´-O-Methyltransferase (50 U/μL)

1.0 μL

【注】：10×Capping Buffer(Cat# 10666)：0.5 M Tris-HCl, 50 mM KCl, 10 mM MgCl2, 10 mM DTT pH 8.0 @ 25°C。

5. 37°C孵育2 h；

6. RNA加帽完成，可进行后续实验。

 

注意事项

1. 为了您的安全和健康，请穿实验服并戴一次性手套操作；

2. 所提取的RNA需经过纯化并使用无核酸酶的水重悬；

3. 在加入酶之前需要对RNA溶液进行加热以去除5'末端的二级结构；

4. 对于已知5'末端结构的RNA，可以延长反应时间至4 h，提高加帽效率；

5. 5'末端标记反应体系中，GTP储液应稀释为反应体系中mRNA摩尔浓度的1-3倍。

HB220701

 

Q: 酶法加帽中先升温再降温的目的是什么？在放大生产时好像很难做到先升温再降温。

A: 先升温是为了把RNA二级结构打开，让RNA处于单链状态。如果不进行这步操作的话，会影响加帽的效率。这部分目前的确是工艺生产上的难点。现在有的公司直接在模板序列确定时会对RNA的二级结构作预测，加帽酶只识别mRNA前几个核苷酸，如果确定这部分结构不会产生RNA的二级结构的话，可以不进行加热。

Q: 帽类似物加帽和酶法加帽如何选择？

A: 工业上酶法加帽最常使用的是牛痘病毒加帽酶处理IVT产物可以将其修饰成Cap 0 mRNA，Cap 0结构可以在二氧甲基转移酶（2'O-methyltransferase）的作用下进一步修饰成Cap 1（m7GpppmN）。利用酶法加帽，加帽效率可以达到95%以上。共转录加帽法操作简便，但由于GTP会竞争帽状二聚体，因此该方法加帽率低一些；两种方式各有优缺点。

Q: 加帽优化的方式有哪些？

A: 通过增加VCE的量例如100ul体系加入10ul即100U的酶活，主要是增强VCE的甲基转移酶活性，也可以通过增加SAM（0.5mmol）增强鸟苷转移活性，增加加帽率。例如我们的新款单链加帽酶，它的加帽率显著提升，就是鸟苷转移活性比传统的更好，对于传统VCE，小亚基D12容易沉淀形成聚合物，纯化时容易损失，所以成本更贵，批次不能控制。

Q: 对于一些没有加上帽子的mRNA，会对后续实验比如说做生物制剂等有什么影响？

A: 目前行业对这一块的没有做针对性的去除，行业里面主要是看加帽效率的多少，目前做的比较好的加帽率在80%以上，当然肯定是越高越好了。这个还没有一个绝对的标准。

对于合成之后的mRNA，可以用纯化的方式处理，比如康*的一步膜包，极大的减少了纯化工艺，传统用Oligo d（T）的柱子做纯化，效果好可以回收率70-80%；效果差40-50%，也可以多加一步疏水柱在oligo dT后。

Q: 共转录加帽和两步法加帽对于模板的起始位点的要求？

A: 共转录要求对于模板的起始位点要求必须是 AGG* 开头

两步法对于位点无要求，但我司目前产品对于AGGG起始位点的产量最高，主要是T7酶的偏好性导致。

牛痘病毒加帽酶 mRNA加帽反应|Vaccinia Capping Enzyme

暂无内容

mRNA Cap 2氧甲基转移酶GMP级|mRNA Cap 2´-O-Methyltransferase GMP-grade

发表于由

mRNA Cap 2氧甲基转移酶GMP级|mRNA Cap 2´-O-Methyltransferase GMP-grade

产品说明书

FAQ

COA

已发表文献

Product Description

mRNA Cap 2´-O-Methyltransferase is a recombinant protein derived from vaccinia virus. The enzyme can add a methyl group at the 2´-O position of the first nucleotide of the cap structure at the 5´ end of the RNA. The enzyme uses SAM as a methyl donor to methylate capped RNA to form a Cap1 structure. The Cap1 structure can enhance the translation efficiency of mRNA, so it can improve the expression of mRNA in transfection and microinjection experiments. This enzyme requires RNA with m7GpppN, a 7-methylguanosine cap structure, as a substrate.

This product is produced in accordance with GMP process requirements. The product is provided in liquid form and can be used for Cap1 capping reaction of pre-mRNA in vivo/in vitro.

 

Product Properties

Source

Recombinant E.coli with Cap 2´-O-Methyltransferase gene

Optimum Temperature

37℃

Storage Buffer

20 mM Tris-HCl pH8.0，0.1mM EDTA，1mM DTT，100mM NaCl，50%（v/v）glycerin，0.1%（v/v）Trion X-100  

Unit Definition

One unit is defined as the amount of enzyme required to methylate 10 pmol of 80nt capped RNA transcript in 1 h at 37°C.

 

Contents

Contents No.

Name

Catalog No./Specification

10612ES92

(10 KU)

10612ES97

(50 KU)

10612ES98

(250 KU)

10612ES99

(20 MU)

10612

mRNA Cap 2´-O-Methyltransferase GMP-grade (50 U/μL)

200 μL

1 mL

5 mL

400 mL

 

Shipping and Storage

The mRNA Cap 2´-O-Methyltransferase GMP-grade products are shipped with dry ice and can be stored at -15℃ ~ -25℃ for one year.

 

Experimental methods

Cap1 capping reaction (20 μL reaction system)

This step is suitable for capping reaction of 10 μg RNA (≥ 100 nt), and can be amplified according to experimental needs.

1. Take 10 μg RNA to a 1.5 mL centrifuge tube and dilute to 12.9 μL with nuclease-free water;

2. Heat at 65°C for 5 min;

3. Take out the centrifuge tube and place it on ice for 5 min;

4. Add the following components in sequence:

Components

Volume

Denatured RNA

12.9 μL

10×Capping Buffer

2.0 μL

Murine RNase inhibitor(40 U/μL)

0.5 μL

GTP (10 mM)

1.0 μL

SAM (10 mM, fresh)

1.6 μL

Vaccinia Capping Enzyme (10 U/μL)

1.0 μL

Cap 2´-O-Methyltransferase (50 U/μL)

1.0 μL

【Note】10×Capping Buffer(Cat# 10666)：0.5 M Tris-HCl, 50 mM KCl, 10 mM MgCl2, 10 mM DTT pH 8.0@25°C.

5. Incubate at 37°C for 2 h; 

6. RNA capping is completed, next experiments can be performed.

 

Notes

1. For your safety and health, please wear personal protective equipment (PPE), such as laboratory coats and disposable gloves, when operating with this product.

2. The extracted RNA needs to be purified and resuspended in nuclease-free water;

3. The RNA solution needs to be heated before adding the enzyme to remove the secondary structure at the 5'end;

4. For RNA with a known 5'end structure, the reaction time can be extended to 4 h to improve the capping efficiency;

5. In the 5'end labeling reaction system, the GTP stock solution should be diluted to 1-3 times of the mRNA molar concentration in the reaction system.

HB230818

mRNA Cap 2氧甲基转移酶GMP级|mRNA Cap 2´-O-Methyltransferase GMP-grade

暂无内容

mRNA Cap 2氧甲基转移酶GMP级|mRNA Cap 2´-O-Methyltransferase GMP-grade

暂无内容

Product Description

mRNA Cap 2´-O-Methyltransferase is a recombinant protein derived from vaccinia virus. The enzyme can add a methyl group at the 2´-O position of the first nucleotide of the cap structure at the 5´ end of the RNA. The enzyme uses SAM as a methyl donor to methylate capped RNA to form a Cap1 structure. The Cap1 structure can enhance the translation efficiency of mRNA, so it can improve the expression of mRNA in transfection and microinjection experiments. This enzyme requires RNA with m7GpppN, a 7-methylguanosine cap structure, as a substrate.

This product is produced in accordance with GMP process requirements. The product is provided in liquid form and can be used for Cap1 capping reaction of pre-mRNA in vivo/in vitro.

 

Product Properties

Source

Recombinant E.coli with Cap 2´-O-Methyltransferase gene

Optimum Temperature

37℃

Storage Buffer

20 mM Tris-HCl pH8.0，0.1mM EDTA，1mM DTT，100mM NaCl，50%（v/v）glycerin，0.1%（v/v）Trion X-100  

Unit Definition

One unit is defined as the amount of enzyme required to methylate 10 pmol of 80nt capped RNA transcript in 1 h at 37°C.

 

Contents

Contents No.

Name

Catalog No./Specification

10612ES92

(10 KU)

10612ES97

(50 KU)

10612ES98

(250 KU)

10612ES99

(20 MU)

10612

mRNA Cap 2´-O-Methyltransferase GMP-grade (50 U/μL)

200 μL

1 mL

5 mL

400 mL

 

Shipping and Storage

The mRNA Cap 2´-O-Methyltransferase GMP-grade products are shipped with dry ice and can be stored at -15℃ ~ -25℃ for one year.

 

Experimental methods

Cap1 capping reaction (20 μL reaction system)

This step is suitable for capping reaction of 10 μg RNA (≥ 100 nt), and can be amplified according to experimental needs.

1. Take 10 μg RNA to a 1.5 mL centrifuge tube and dilute to 12.9 μL with nuclease-free water;

2. Heat at 65°C for 5 min;

3. Take out the centrifuge tube and place it on ice for 5 min;

4. Add the following components in sequence:

Components

Volume

Denatured RNA

12.9 μL

10×Capping Buffer

2.0 μL

Murine RNase inhibitor(40 U/μL)

0.5 μL

GTP (10 mM)

1.0 μL

SAM (10 mM, fresh)

1.6 μL

Vaccinia Capping Enzyme (10 U/μL)

1.0 μL

Cap 2´-O-Methyltransferase (50 U/μL)

1.0 μL

【Note】10×Capping Buffer(Cat# 10666)：0.5 M Tris-HCl, 50 mM KCl, 10 mM MgCl2, 10 mM DTT pH 8.0@25°C.

5. Incubate at 37°C for 2 h; 

6. RNA capping is completed, next experiments can be performed.

 

Notes

1. For your safety and health, please wear personal protective equipment (PPE), such as laboratory coats and disposable gloves, when operating with this product.

2. The extracted RNA needs to be purified and resuspended in nuclease-free water;

3. The RNA solution needs to be heated before adding the enzyme to remove the secondary structure at the 5'end;

4. For RNA with a known 5'end structure, the reaction time can be extended to 4 h to improve the capping efficiency;

5. In the 5'end labeling reaction system, the GTP stock solution should be diluted to 1-3 times of the mRNA molar concentration in the reaction system.

HB230818

mRNA Cap 2氧甲基转移酶GMP级|mRNA Cap 2´-O-Methyltransferase GMP-grade

暂无内容

mRNA Cap 2氧甲基转移酶GMP级|mRNA Cap 2´-O-Methyltransferase GMP-grade

暂无内容

Hieff Trans® mRNA转染试剂(mRNA Transfection Reagent)

发表于由

Hieff Trans® mRNA转染试剂(mRNA Transfection Reagent)

产品说明书

FAQ

COA

已发表文献

 

Hieff Trans® mRNA转染试剂是一款针对mRNA细胞转染的阳离子多聚物转染试剂，对常规细胞、原代细胞、神经细胞都具有较高的转染效率。其独特的配方使其可直接加入培养基中，血清的存在不会影响转染效率，这样可以减少去除血清对细胞的损伤。转染后不需要除去核酸–转染试剂复合物或更换新鲜培养基，也可根据细胞营养状态在4-6小时后更换新鲜培养基。

 

运输与保存方法

冰袋（wet ice）运输。产品2-8ºC保存，一年有效。不可冷冻！

 

注意事项

1）转染操作时，以细胞融合度达70%-80%为佳，具体铺板密度根据细胞情况酌情而定。

2）制备转染复合物时要求用无血清培养基稀释mRNA和转染试剂。

3）使用无RNA酶污染的耗材与试剂。

4）2-8ºC保存，要注意避免多次反复长时间开盖。

5）初次使用应优化核酸浓度和试剂量以得到最高的转染效率。

6）本产品仅作科研用途！

 

操作流程（以24孔板为例，其他培养板加样体积请参考表一）

注：转染试剂使用量受细胞类型及其他实验条件影响，建议初次使用时设置梯度进行优化最佳使用量。

1. 细胞铺板，至转染操作时，以细胞融合度达70%-80%为佳。

2. 按照以下体系配制mRNA–转染试剂复合物：

1）对于每孔细胞，使用10 μL无血清培养基（如OPTI-MEM培养基）稀释0.4 μg mRNA，轻轻混匀。

2）对于每孔细胞，使用10 μL无血清培养基（如OPTI-MEM培养基）稀释0.8–1.6 μL转染试剂，轻轻混匀，室温孵育5 min。

3）将稀释的mRNA与稀释的转染试剂轻轻混匀。

4）室温静置孵育20 min。

3. 将mRNA-转染试剂复合物逐滴加到细胞中，轻轻混匀。

4. 37℃，5% CO2培养箱培养24-96 h，直至进行基因表达分析。

 

不同细胞培养容器转染用量（仅供参考）：

培养容器

表面积

每孔体积

mRNA转染

培养基体积

稀释液体积

mRNA

试剂体积

96-well

0.3 cm2

100 μL

2×5 μL

0.2 μg

0.2-0.4 μL

24-well

2 cm2

500 μL

2×10 μL

0.4 μg

0.8-1.6 μL

12-well

4 cm2

1 mL

2×20 μL

0.8 μg

1.6-3.2 μL

6-well

10 cm2

2 mL

2×50 μL

1 μg

2-4 μL

60-mm

20 cm2

5 mL

2×100 μL

4 μg

8-16 μL

10-cm

60 cm2

15 mL

2×300 μL

12 μg

24-48 μL

【注】该表使用量仅供参考，mRNA与转染试剂具体使用量还需根据细胞类型及其他实验条件进行优化。建议使用时比值保持在1:0.5-1:5之间。

HB221102

Q：40809主要成分是PEI吗？

A：不是，是类似LNP的组分。

Hieff Trans® mRNA转染试剂(mRNA Transfection Reagent)

暂无内容

 

Hieff Trans® mRNA转染试剂是一款针对mRNA细胞转染的阳离子多聚物转染试剂，对常规细胞、原代细胞、神经细胞都具有较高的转染效率。其独特的配方使其可直接加入培养基中，血清的存在不会影响转染效率，这样可以减少去除血清对细胞的损伤。转染后不需要除去核酸–转染试剂复合物或更换新鲜培养基，也可根据细胞营养状态在4-6小时后更换新鲜培养基。

 

运输与保存方法

冰袋（wet ice）运输。产品2-8ºC保存，一年有效。不可冷冻！

 

注意事项

1）转染操作时，以细胞融合度达70%-80%为佳，具体铺板密度根据细胞情况酌情而定。

2）制备转染复合物时要求用无血清培养基稀释mRNA和转染试剂。

3）使用无RNA酶污染的耗材与试剂。

4）2-8ºC保存，要注意避免多次反复长时间开盖。

5）初次使用应优化核酸浓度和试剂量以得到最高的转染效率。

6）本产品仅作科研用途！

 

操作流程（以24孔板为例，其他培养板加样体积请参考表一）

注：转染试剂使用量受细胞类型及其他实验条件影响，建议初次使用时设置梯度进行优化最佳使用量。

1. 细胞铺板，至转染操作时，以细胞融合度达70%-80%为佳。

2. 按照以下体系配制mRNA–转染试剂复合物：

1）对于每孔细胞，使用10 μL无血清培养基（如OPTI-MEM培养基）稀释0.4 μg mRNA，轻轻混匀。

2）对于每孔细胞，使用10 μL无血清培养基（如OPTI-MEM培养基）稀释0.8–1.6 μL转染试剂，轻轻混匀，室温孵育5 min。

3）将稀释的mRNA与稀释的转染试剂轻轻混匀。

4）室温静置孵育20 min。

3. 将mRNA-转染试剂复合物逐滴加到细胞中，轻轻混匀。

4. 37℃，5% CO2培养箱培养24-96 h，直至进行基因表达分析。

 

不同细胞培养容器转染用量（仅供参考）：

培养容器

表面积

每孔体积

mRNA转染

培养基体积

稀释液体积

mRNA

试剂体积

96-well

0.3 cm2

100 μL

2×5 μL

0.2 μg

0.2-0.4 μL

24-well

2 cm2

500 μL

2×10 μL

0.4 μg

0.8-1.6 μL

12-well

4 cm2

1 mL

2×20 μL

0.8 μg

1.6-3.2 μL

6-well

10 cm2

2 mL

2×50 μL

1 μg

2-4 μL

60-mm

20 cm2

5 mL

2×100 μL

4 μg

8-16 μL

10-cm

60 cm2

15 mL

2×300 μL

12 μg

24-48 μL

【注】该表使用量仅供参考，mRNA与转染试剂具体使用量还需根据细胞类型及其他实验条件进行优化。建议使用时比值保持在1:0.5-1:5之间。

HB221102

Q：40809主要成分是PEI吗？

A：不是，是类似LNP的组分。

Hieff Trans® mRNA转染试剂(mRNA Transfection Reagent)

暂无内容

ADS Biotec ——核酸（MRNA）纯化*

发表于由

 

 

ADS Biotec ——核酸（MRNA）纯化*

 

 

 

 

色谱柱订购信息
产品描述 货号 规格 应用
RNASep™ Prep Column RNA
–
99
–
3810 7.8 x 50 mm RNA分子的分离纯化及质量 控制
RNASep™ Semi–Prep Column RPC
–
99
–
2110 21.2 x 100 mm 用于中间放大的RNA纯化 RNASep
™
Semi–Prep II Column RPC
–
99
–
3015 30.0 x 150 mm 大规模放大的RNA纯化
DNASep™ Column DNA
–
99
–
3510 4.6 x 50 mm 高分辨率ds/ssRNA与DNA分析
高分辨率RNA分析

缓冲液订购信息
产品描述 货号 规格 应用
Triethylammonium Acetate Buffer A(0.1 M TEAA in water)
553421 4 x 2.5 L  Phase for Nucleic Acid
Analysis
Triethylammonium Acetate Buffer A(0.1 M TEAA in water)
553421
–
L4 4 x 4 L
Triethylammonium Acetate
Buffer B (0.1 M TEAA in 25 % Acetonitrile)
553422 4 x 2.5L  Phase for Nucleic Acid
Analysis
Triethylammonium Acetate Buffer B (0.1 M TEAA in 25 % Acetonitrile)
553422
–
L4 4 x 4 L
HPLC Column Wash Solution D
(75 % acetonitrile)
553423 4 x 2.5 L
HPLC Column Wash Solution D
(75 % acetonitrile)
553423
–
L4 4 x 4 L

 

对标竞品
货号 品名 对标货号 对标品牌 品名 规格
SP5890 2 M TEAA Solution
(6*200ml )
400613 Invitrogen 三乙胺乙酸 (TEAA)
2.0 M
200ml
69372
–
250ML
sigma Triethylammoniu
m acetate (TEAA)
（0.98–1.02 M 250 mL/瓶
（￥ 1800）

 

 

 

TriLink Genome Editing mRNA 现货

发表于由

上海金畔生物科技正规代理Trilink产品，zui近市场出现Trilink的假货，为了您的实验安全请选择正牌代理。 :

 

 

TriLink BioTechnologies——高品质常规/特殊核苷酸产品
TriLink BioTechnologies公司是世界的核酸修饰技术领域的，成立于1996年，总部设在San Diego，California。TriLink公司致力于高品质核酸修饰产品的研发和生产，提供包括核苷酸、常规及核苷三磷酸特殊修饰的寡核苷酸定制（oligonucleotides），m RNA合成，CleanAmp?PCR产品，phosphoramidites和其他小分子在内的众多产品。近二十年来，TriLink一直是诊断和OEM市场核酸产品供应的行业，产品应用于基因治疗，核苷类化疗，寡核苷酸治疗和诊断领域。此外，TriLink还可提供特殊核苷酸、m RNA定制，合同研究服务和ISO/ QSR标准的cGMP生产设施。TriLink完善的产品及研发服务解决方案有助于推动药物发现和生物医学研究。

经过18年的发展， TriLink已经成为高品质RNA合成领域的，为广大科研工作者提供的mRNA及长链RNA（长可达几个Kb），并且定制修饰。同时我们也提供成品mRNA产品，包括报告基因及 mRNA表达因子。

Genome Editing mRNA

Plasmids and viral vectors have traditionally been used in genome editing to express the required proteins inside cells or an organism. However, editing DNA carries a risk. Double stranded DNA breaks catalyze insertion of DNA at the cut site. At some substantial frequency, the protein expression vectors can integrate, which can lead to continuous expression of the nuclease or a previously silent sequence.

Now mRNA is being used in genome editing to transiently express the required proteins. With no risk of insertional mutagenesis, it is a powerful tool. Additionally synthetic mRNA, which mimics fully processed, capped and polyadenylated mRNA, can be produced in large quantities by in vitro transcription and modified to reduce innate immune stimulation.

产品如下：

货号 品名 规格 价格 品牌
Genome Editing mRNA  
L-7206 CleanCap™ Cas9 mRNA (modified) 20 µgrams  2550 TriLink BioTechnologies
L-7206 CleanCap™ Cas9 mRNA (modified) 100 µgrams 6035 TriLink BioTechnologies
L-7206 CleanCap™ Cas9 mRNA (modified) 1 mg 31875 TriLink BioTechnologies
L-7206 CleanCap™ Cas9 mRNA (modified) 5 mg (5 x 1 mg)  114750 TriLink BioTechnologies
L-7211 CleanCap™ Cre mRNA (5moU) 5moU 询价 TriLink BioTechnologies
L-7207 CleanCap™ Cas9 Nickase mRNA (5moU) 20 µgrams  2550 TriLink BioTechnologies
L-7207 CleanCap™ Cas9 Nickase mRNA (5moU) 100 µgrams 6035 TriLink BioTechnologies
L-7207 CleanCap™ Cas9 Nickase mRNA (5moU) 1 mg 31875 TriLink BioTechnologies
L-7207 CleanCap™ Cas9 Nickase mRNA (5moU) 5 mg (5 x 1 mg)  114750 TriLink BioTechnologies
L-7606 CleanCap™ Cas9 mRNA 20 µgrams  2125 TriLink BioTechnologies
L-7606 CleanCap™ Cas9 mRNA 100 µgrams 5015 TriLink BioTechnologies
L-7606 CleanCap™ Cas9 mRNA 1 mg 26775 TriLink BioTechnologies
L-7606 CleanCap™ Cas9 mRNA 5 mg (5 x 1 mg)  96050 TriLink BioTechnologies

 

Zinc-finger Nuclease mRNA (ZFN mRNA)

Zinc-finger nucleases (ZFNs) were the first widely applicable site specific genome editing tools. Recently, several studies have shown that ZFNs can have off-target effects at non-targeted chromosomal sites that are similar in sequence to the intended target site. For this reason, there is a move to transient ZFN expression using mRNA based vectors. TriLink’s custom mRNA transcription service includes ZFN mRNA. Request a quote today!

L-7206
CleanCap™ Cas9 mRNA (modified)
CleanCap™ CRISPR Associated Protein 9 mRNA (U-modified) 

mRNA Length: 4,521 nucleotides

Concentration: 1.0 mg/mL

Buffer: 1 mM Sodium Citrate, pH 6.4

Identity & Purity:

Agarose Gel Mobility; Pass

Concentration ± 5%; Pass

Product Insert
SDS

Cas9 mRNA expresses a version of the Streptococcus pyogenes SF370 Cas9 protein (CRISPR Associated Protein 9). Cas9 functions as part of the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) genome editing system. In the CRISPR system, an RNA guide sequence targets the site of interest and the Cas9 protein is employed to perform double stranded DNA cleavage.

Cas9 mRNA encodes the Cas9 protein with an N and C terminal nuclear localization signal (NLS). The incorporation of two NLS signals within the mRNA increases the frequency of delivery to the nucleus, thus increasing the rate of DNA cleavage. Additionally, a C terminal HA epitope tag aids detection, isolation, and purification of the Cas9 protein.

This mRNA is capped using CleanCap™, TriLink's proprietary co-transciptional capping method, which results in the naturally occuring Cap 1 structure with high capping efficiency. It is polyadenylated, substituted with a modified uridine and optimized for mammalian systems. It mimics a fully processed mature mRNA.

Certificate(s) of Analysis

TD-OA02A

T1-CHZ01A-1 

L-7206 is a replacement product for L-6125 and L-6129. 

Not for resale without express written permission. Not for use in humans. No license under any patent or patent pending is granted or implied by the purchase of any TriLink product. TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser’s sole responsibility.

 

CleanCap™ Cre mRNA (5moU)
CleanCap™ NLS-Cre Recombinase mRNA (5-methoxyuridine) 

Contact us today to preorder! 

Catalog Number: L-7211 

mRNA Length: 1,437 nucleotides

Concentration: 1.0 mg/mL

Buffer: 1 mM Sodium Citrate, pH 6.4

Identity & Purity:

Agarose Gel Mobility; Pass

Concentration ± 5%; Pass

Product Insert
SDS

NLS-Cre Recombinase mRNA is a capped and polyadenylated messenger RNA encoding Cre recombinase fused to a nuclear localization sequence (NLS). Cre recombinase is a tyrosine recombinase that catalyzes recombination between two loxP sites.

This mRNA is capped using CleanCap™, TriLink's proprietary co-transciptional capping method, which results in the naturally occuring Cap 1 structure with high capping efficiency. It is polyadenylated, modified with 5-methoxyuridine and optimized for mammalian systems. It mimics a fully processed mature mRNA.

L-7211 is a replacement for L-6108.

Not for resale without express written permission. Not for use in humans. No license under any patent or patent pending is granted or implied by the purchase of any TriLink product. TriLink does not warrant that the use or sale of the products delivered hereunder will not infringe the claims of any United States or other patents or patents pending covering the use of the product alone or in combination with other products or in the operation of any process. All and any use of TriLink product is the purchaser’s sole responsibility.

L-7606
CleanCap™ Cas9 mRNA
CleanCap™ CRISPR Associated Protein 9 mRNA 

mRNA Length: 4,521 nucleotides

Concentration: 1.0 mg/mL

Buffer: 1 mM Sodium Citrate, pH 6.4

Identity & Purity:

Agarose Gel Mobility; Pass

Concentration ± 5%; Pass

Product Insert
SDS

Cas9 mRNA expresses a version of the Streptococcus pyogenes SF370 Cas9 protein (CRISPR Associated Protein 9). Cas9 functions as part of the CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) genome editing system. In the CRISPR system, an RNA guide sequence targets the site of interest and the Cas9 protein is employed to perform double stranded DNA cleavage.

Cas9 mRNA encodes the Cas9 protein with an N and C terminal nuclear localization signal (NLS). The incorporation of two NLS signals within the mRNA increases the frequency of delivery to the nucleus, thus increasing the rate of DNA cleavage. Additionally, a C terminal HA epitope tag aids detection, isolation, and purification of the Cas9 protein. 

This mRNA is capped using CleanCap™, TriLink's proprietary co-transciptional capping method, which results in the naturally occuring Cap 1 structure with high capping efficiency. It is polyadenylated, and optimized for mammalian systems. It mimics a fully processed mature mRNA.